	CANDE CE A TEMENT	Docket No.
TDANSMITTAL OF INFURIVATION DISCLOSURE STATEMENT		Army172
(Under 37 CFR 1.97(b) or 1.97(c))		
In Re Application Of: Ulrich et al. MAR 0 7 2003		P#/
	Examiner	Group Art Unit
Serial Filing Date	not known	1634
10/002,784 17RAD MARKS 11/26/01	not into	
Title: Bacterial Superantigen Vaccines		TECH CENTER CO.
	Address to:	600
Assistant Commissioner for Patents Washington, D.C. 20231		
37	CFR 1.97(b)	
The Information Disclosure Statement submitted of a national application other than a continue three months of the date of entry of the nationapplication; before the mailing of a first Office A Action after the filing of a request for continued.	al stage as set forth in 37 CFR 1. Action on the merits, or before the	491 in an international mailing of a first Office
37	CFR 1.97(c)	
2. The Information Disclosure Statement submitted CFR 1.97(b), provided that the Information Disclosure Statement submitted CFR 1.97(b), provided that the Information Disclosure Statement submitted CFR 1.97(b), provided that the Information Disclosure Statement submitted CFR 1.97(b), provided that the Information Disclosure Statement submitted CFR 1.97(b), provided that the Information Disclosure Statement submitted CFR 1.97(b), provided that the Information Disclosure Statement submitted CFR 1.97(b), provided that the Information Disclosure Statement submitted CFR 1.97(b), provided that the Information Disclosure Statement submitted CFR 1.97(b), provided that the Information Disclosure Statement submitted CFR 1.97(b), provided that the Information Disclosure Statement submitted CFR 1.97(b), provided that the Information Disclosure Statement submitted CFR 1.97(b), provided that the Information Disclosure Statement submitted CFR 1.97(b), provided that the Information Disclosure Statement submitted CFR 1.97(b), provided that the Information Disclosure Statement submitted CFR 1.97(b), provided that the Information Statement submitted CFR 1.97(b), pr	of Allowance under 37 CFR 1.3	e period specified in 37 e the mailing date of a 311, or an Action that
the statement specified in 37 CFR 1.97(e);	
OR		
☐ the fee set forth in 37 CFR 1.17(p).		
	•	

FRANSMITTAL OF INFORMATION DISCLO (Under 37 CFR 1.97(b) or 1.97	SURE STATEMENT Docket No. (c) Army172	
In Re Application: Ulrich et al.		
Serial No. Filing Date	Examiner Group art Unit	
10/002,784 TRADEMARK 11/26/01	not known	
Bacterial Superantigen Vaccines	Examiner Group Art Unit	
Pavi	ment of Fee	
	ects to pay the fee set forth in 37 CFR 1.17(p))	
 □ A check in the amount of is attained. ☑ The Assistant Commissioner is hereby authorized as described below. A duplicate copy of this sheet. □ Charge the amount of □ Credit any overpayment. ☑ Charge any additional fee required. Certificate of Transmission by Facsimile* 	It to charge and credit Deposit Account No. 21-0380 et is enclosed. Certificate of Mailing by First Class Mail	
I certify that this document and authorization to charge deposi account is being facsimile transmitted to the United States Patent and Trademark Office (F	I certify that this document and fee is being deposited March 5, 2003 with the U.S. Postal Service as first class mail under SY C.P.R. 1.8 and is addressed to the Assistant Commissioner for Patents Washington, D.C. 20231	
(Date)	Signature of Person Mailing Correspondence	
Signature	Marlana Titus	
Typed or Printed Name of Person Signing Certificate	Typed or Printed Name of Person Mailing Certificate	
*This certificate may only be used if paying by deposit account. Signature	Dated: March 5, 2003	
Marlana Titus, Reg. No.35,843	•	
Attorney for applicant		
Attorney for applicant US Medical Research and Materiel Command		
for Elizabeth Arwine, Reg. No.45,867 Attorney for applicant US Medical Research and Materiel Command 504 Scott Street Fort Detrick, MD 21702-5012		

cc: